当前位置: 首页 >> 检索结果
810. Tackling cardiovascular disease in the Asia-Pacific region: a new Lancet Commission.
作者: Carolyn S P Lam.;F Aaysha Cader.;Nicholas W S Chew.;Clara K Chow.;Corina Grey.;Yuming Guo.;Adam J Nelson.;Anna Rolleston.;Mitsuaki Sawano.;Kathryn Choon Beng Tan.;Jasper Tromp.;Lijing L Yan.;Stephen J Nicholls.
来源: Lancet. 2025年406卷10507期988-989页 812. Efficacy and safety of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy versus Roux-en-Y gastric bypass in France (SADISLEEVE): results of a randomised, open-label, superiority trial at 2 years of follow-up.
作者: Maud Robert.;Tigran Poghosyan.;Nicolas Romain-Scelle.;Sebastien Czernichow.;Dominique Delaunay.;Adrien Sterkers.;Litavan Khamphommala.;Andrea Lazzati.;Claire Blanchard.;Robert Caiazzo.;François Pattou.;Emmanuel Disse.; .
来源: Lancet. 2025年406卷10505期846-859页
Since 2007, single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) has been proposed as an alternative to Roux-en-Y gastric bypass (RYGB) in the treatment of obesity. We conducted a multicentre randomised trial, with the hypothesis that SADI-S could be more effective than RYGB at 2-year follow-up.
813. Building community capacity in mental health care with the Strong Minds-Strong Communities programme: a randomised controlled trial in the USA.
作者: Margarita Alegría.;Gabriela Livas Stein.;Mario Cruz-Gonzalez.;Irene Falgas-Bague.;Sheri Lapatin Markle.;Kari M Eddington.;Andrew Supple.;Larimar Fuentes.;Claire Poindexter.;Patrick E Shrout.
来源: Lancet. 2025年406卷10505期832-845页
Provider shortages and lack of culturally responsive care limit mental health services in reaching multicultural populations worldwide. We examined the effectiveness of a psychoeducational intervention aimed at building community capacity to address depression and anxiety among racial, ethnic, and linguistic minoritised adults.
814. Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
作者: Rohit Loomba.;Erin Morgan.;Keyvan Yousefi.;Dan Li.;Richard Geary.;Sanjay Bhanot.;Naim Alkhouri.; .
来源: Lancet. 2025年406卷10505期821-831页
ION224, a liver-directed antisense inhibitor of diacylglycerol O-acyltransferase 2 (DGAT2), suppresses de novo lipogenesis, an important metabolic pathway associated with lipotoxicity and the underlying inflammation, hepatocellular injury, and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). This study aimed to prospectively assess the safety and efficacy of ION224 in patients with MASH and fibrosis.
|